{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:04:37Z","timestamp":1784131477070,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010221","name":"Higher Education Commision, Pakistan","doi-asserted-by":"publisher","award":["NRPU#17226"],"award-info":[{"award-number":["NRPU#17226"]}],"id":[{"id":"10.13039\/501100010221","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"DOI":"10.1007\/s11307-026-02124-6","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:10:35Z","timestamp":1784128235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FcRn-Targeted Alpha Therapy Using [225Ac]Ac-Macropa-Rozanolixizumab Enables Potent Antitumor Activity"],"prefix":"10.1007","author":[{"given":"Saba","family":"Shirin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3145-6070","authenticated-orcid":false,"given":"Syed Qaiser","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Santos-Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2124_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros G, Bodei L, McDevitt MR, Nedrow JR (2020) Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov 19:589\u2013608. https:\/\/doi.org\/10.1038\/s41573-020-0073-9","journal-title":"Nat Rev Drug Discov"},{"key":"2124_CR2","doi-asserted-by":"publisher","first-page":"11626","DOI":"10.3390\/ijms241411626","volume":"24","author":"A Jang","year":"2023","unstructured":"Jang A, Kendi AT, Johnson GB et al (2023) Targeted alpha-particle therapy: a review of current trials. Int J Mol Sci 24:11626. https:\/\/doi.org\/10.3390\/ijms241411626","journal-title":"Int J Mol Sci"},{"key":"2124_CR3","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL et al (2016) 225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer. J Nucl Med 57:1941\u20131944. https:\/\/doi.org\/10.2967\/jnumed.116.178673","journal-title":"J Nucl Med"},{"key":"2124_CR4","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1158\/1078-0432.ccr-12-0298","volume":"19","author":"KE Baidoo","year":"2013","unstructured":"Baidoo KE, Yong K, Brechbiel MW (2013) Molecular pathways: targeted \u03b1-particle radiation therapy. Clin Cancer Res 19:530\u2013537. https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-0298","journal-title":"Clin Cancer Res"},{"key":"2124_CR5","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1021\/acs.bioconjchem.6c00125","volume":"37","author":"SQ Shah","year":"2026","unstructured":"Shah SQ, Santos-Oliveira R, Ilem-Ozdemir D, Shabnam M (2026) IGF2R-targeted alpha therapy of osteosarcoma enabled by conjugated [225 Ac]Ac-Macropa-PEG 4 -IF3. Bioconjug Chem 37:1025\u20131034. https:\/\/doi.org\/10.1021\/acs.bioconjchem.6c00125","journal-title":"Bioconjug Chem"},{"key":"2124_CR6","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715\u2013725. https:\/\/doi.org\/10.1038\/nri2155","journal-title":"Nat Rev Immunol"},{"key":"2124_CR7","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","volume":"10","author":"M Pyzik","year":"2019","unstructured":"Pyzik M, Sand KMK, Hubbard JJ et al (2019) The neonatal Fc receptor (FcRn): a misnomer? Front Immunol 10:1540. https:\/\/doi.org\/10.3389\/fimmu.2019.01540","journal-title":"Front Immunol"},{"key":"2124_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1369\/0022155417705095","volume":"65","author":"S Latvala","year":"2017","unstructured":"Latvala S, Jacobsen B, Otteneder MB et al (2017) Distribution of FcRn across species and tissues. J Histochem Cytochem 65:321\u2013333. https:\/\/doi.org\/10.1369\/0022155417705095","journal-title":"J Histochem Cytochem"},{"key":"2124_CR9","doi-asserted-by":"publisher","first-page":"4580","DOI":"10.4049\/jimmunol.179.7.4580","volume":"179","author":"S Akilesh","year":"2007","unstructured":"Akilesh S, Christianson GJ, Roopenian DC, Shaw AS (2007) Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol 179:4580\u20134588. https:\/\/doi.org\/10.4049\/jimmunol.179.7.4580","journal-title":"J Immunol"},{"key":"2124_CR10","doi-asserted-by":"publisher","first-page":"54415","DOI":"10.18632\/oncotarget.10074","volume":"7","author":"E Dalloneau","year":"2016","unstructured":"Dalloneau E, Baroukh N, Mavridis K et al (2016) Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis. Oncotarget 7:54415\u201354429. https:\/\/doi.org\/10.18632\/oncotarget.10074","journal-title":"Oncotarget"},{"key":"2124_CR11","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/19420862.2018.1505464","volume":"10","author":"B Smith","year":"2018","unstructured":"Smith B, Kiessling A, Lledo-Garcia R et al (2018) Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs 10:1111\u20131130. https:\/\/doi.org\/10.1080\/19420862.2018.1505464","journal-title":"MAbs"},{"key":"2124_CR12","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","volume":"92","author":"JF Howard","year":"2019","unstructured":"Howard JF, Bril V, Burns TM et al (2019) Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology 92:e2661\u2013e2673. https:\/\/doi.org\/10.1212\/WNL.0000000000007600","journal-title":"Neurology"},{"key":"2124_CR13","doi-asserted-by":"publisher","first-page":"eaan1208","DOI":"10.1126\/scitranslmed.aan1208","volume":"9","author":"P Kiessling","year":"2017","unstructured":"Kiessling P, Lledo-Garcia R, Watanabe S et al (2017) The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Sci Transl Med 9:eaan1208. https:\/\/doi.org\/10.1126\/scitranslmed.aan1208","journal-title":"Sci Transl Med"},{"key":"2124_CR14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ajh.25680","volume":"95","author":"AC Newland","year":"2019","unstructured":"Newland AC, S\u00e1nchez-Gonz\u00e1lez B, Rejt\u0151 L et al (2019) Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol 95:178\u2013187. https:\/\/doi.org\/10.1002\/ajh.25680","journal-title":"Am J Hematol"},{"key":"2124_CR15","doi-asserted-by":"publisher","first-page":"14712","DOI":"10.1002\/anie.201709532","volume":"56","author":"NA Thiele","year":"2017","unstructured":"Thiele NA, Brown V, Kelly JM et al (2017) An eighteen-membered macrocyclic ligand for Actinium-225 targeted alpha therapy. Angew Chem 56:14712\u201314717. https:\/\/doi.org\/10.1002\/anie.201709532","journal-title":"Angew Chem"},{"key":"2124_CR16","doi-asserted-by":"publisher","unstructured":"Shah SQ, Santos-Oliveira R, Shabnam M, DeryaIlem-Ozdemir (2026) Mesothelin-targeted alpha therapy in PDAC with [225Ac]Ac-Macropa-PEG6-Amatuximab. Nucl Med Biol 154\u2013155:109606. https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109606","DOI":"10.1016\/j.nucmedbio.2026.109606"},{"key":"2124_CR17","doi-asserted-by":"publisher","first-page":"7203","DOI":"10.7150\/thno.78043","volume":"12","author":"F Reissig","year":"2022","unstructured":"Reissig F, Zarschler K, Novy Z et al (2022) Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin. Theranostics 12:7203\u20137215. https:\/\/doi.org\/10.7150\/thno.78043","journal-title":"Theranostics"},{"key":"2124_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4161\/mabs.27022","volume":"6","author":"S Panowski","year":"2013","unstructured":"Panowski S, Bhakta S, Raab H et al (2013) Site-specific antibody drug conjugates for cancer therapy. MAbs 6:34\u201345. https:\/\/doi.org\/10.4161\/mabs.27022","journal-title":"MAbs"},{"key":"2124_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.2108","volume":"30","author":"B-Q Shen","year":"2012","unstructured":"Shen B-Q, Xu K, Liu L et al (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 30:184\u2013189. https:\/\/doi.org\/10.1038\/nbt.2108","journal-title":"Nat Biotechnol"},{"key":"2124_CR20","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nbt.1480","volume":"26","author":"JR Junutula","year":"2008","unstructured":"Junutula JR, Raab H, Clark S et al (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925\u2013932. https:\/\/doi.org\/10.1038\/nbt.1480","journal-title":"Nat Biotechnol"},{"key":"2124_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4161\/mabs.26632","volume":"6","author":"CR Behrens","year":"2013","unstructured":"Behrens CR, Liu B (2013) Methods for site-specific drug conjugation to antibodies. MAbs 6:46\u201353. https:\/\/doi.org\/10.4161\/mabs.26632","journal-title":"MAbs"},{"key":"2124_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0022-1759(84)90435-6","volume":"72","author":"T Lindmo","year":"1984","unstructured":"Lindmo T, Boven E, Cuttitta F et al (1984) Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72:77\u201389. https:\/\/doi.org\/10.1016\/0022-1759(84)90435-6","journal-title":"J Immunol Methods"},{"key":"2124_CR23","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1016\/S1470-2045(17)30379-0","volume":"18","author":"MR Gill","year":"2017","unstructured":"Gill MR, Falzone N, Du Y, Vallis KA (2017) Targeted radionuclide therapy in combined-modality regimens. Lancet Oncol 18:e414\u2013e423. https:\/\/doi.org\/10.1016\/S1470-2045(17)30379-0","journal-title":"Lancet Oncol"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-026-02124-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-026-02124-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-026-02124-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:10:36Z","timestamp":1784128236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-026-02124-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":23,"alternative-id":["2124"],"URL":"https:\/\/doi.org\/10.1007\/s11307-026-02124-6","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal procedures were approved by the IACUC (protocol 24-NMRL-015) per NIH guidelines.","order":1,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No human participants.","order":2,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interests.","order":3,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}